Format

Send to

Choose Destination

See 1 citation found by title matching your search:

Clin Cancer Res. 2017 Aug 15;23(16):4919-4928. doi: 10.1158/1078-0432.CCR-16-2656. Epub 2017 Apr 26.

Enrichment of PI3K-AKT-mTOR Pathway Activation in Hepatic Metastases from Breast Cancer.

Author information

1
George Mason University, Manassas, Virginia.
2
Theranostics Health, Rockville, Maryland.
3
Translational Genomics Research Institute, Phoenix, Arizona.
4
Evergreen Hematology & Oncology, Spokane, Washington.
5
Virginia Cancer Specialists/US Oncology, Fairfax, Virginia.
6
Division of Hematology/Oncology, Mayo Clinic Arizona, Scottsdale, Arizona.
7
University of Miami Sylvester Comprehensive Cancer Center Deerfield Campus, Deerfield Beach, Florida.
8
TD2 Translational Drug Development, Scottsdale, Arizona.
9
The Side Out Foundation, Fairfax, Virginia.
10
Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois.
11
Avera Cancer Institute Center for Precision Oncology, Sioux Falls, South Dakota.
12
Texas Oncology, Baylor-Sammons Cancer Center, Dallas, Texas.
13
George Mason University, Manassas, Virginia. epetrico@gmu.edu.

Abstract

Purpose: Little is known about the molecular signatures associated with specific metastatic sites in breast cancer. Using comprehensive multi-omic molecular profiling, we assessed whether alterations or activation of the PI3K-AKT-mTOR pathway is associated with specific sites of breast cancer metastasis.Experimental Design: Next-generation sequencing-based whole-exome sequencing was coupled with reverse-phase protein microarray (RPPA) functional signaling network analysis to explore the PI3K-AKT-mTOR axis in 32 pretreated breast cancer metastases. RPPA-based signaling data were further validated in an independent cohort of 154 metastatic lesions from breast cancer and 101 unmatched primary breast tumors. The proportion of cases with PI3K-AKT-mTOR genomic alterations or signaling network activation were compared between hepatic and nonhepatic lesions.Results:PIK3CA mutation and activation of AKT (S473) and p70S6K (T389) were detected more frequently among liver metastases than nonhepatic lesions (P < 0.01, P = 0.056, and P = 0.053, respectively). However, PIK3CA mutations alone were insufficient in predicting protein activation (P = 0.32 and P = 0.19 for activated AKT and p70S6K, respectively). RPPA analysis of an independent cohort of 154 tumors confirmed the relationship between pathway activation and hepatic metastasis [AKT (S473), mTOR (S2448), and 4EBP1 (S65); P < 0.01, P = 0.02, and P = 0.01, respectively]. Similar results were also seen between liver metastases and primary breast tumors [AKT (S473) P < 0.01, mTOR (S2448) P < 0.01, 4EBP1 (S65) P = 0.01]. This signature was lost when primary tumors were compared with all metastatic sites combined.Conclusions: Breast cancer patients with liver metastasis may represent a molecularly homogenized cohort with increased incidence of PIK3CA mutations and activation of the PI3K-AKT-mTOR signaling network. Clin Cancer Res; 23(16); 4919-28. ©2017 AACR.

PMID:
28446508
PMCID:
PMC5564311
DOI:
10.1158/1078-0432.CCR-16-2656
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center